May. 8 at 1:41 PM
$NMTC A big med device company should scoop up
$NMTC now while it’s still early. They’ve got FDA-cleared tech for brain disorders and pain that’s less invasive and cheaper than what’s out there today. The neuro space is growing fast, and
$NMTC’s already cleared key regulatory hurdles. They’re ready to scale but need more muscle behind them. This is a no-brainer bolt-on that could punch above its weight for companies like
$ABT,
$BSX,
$SYK, or
$ZBH looking to expand in neuromodulation and brain health.
